Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.
0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Jovany J Betancourt *Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0003-0364-4816
Minna Ding *Department of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
J Marina YoderDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Issa MutyabaDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.
Hannah M AtkinsDivision of Comparative Medicine, Department of Pathology and Laboratory Medicine, University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA.
Gabriela De la CruzPathology Services Core, University of North Carolina Chapel Hill, Chapel Hill, North Carolina, USA.
David B MeyaCollege of Health Sciences, Makerere University, Kampala, Uganda.
Kirsten NielsenDepartment of Microbiology and Immunology, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-2318-168X
Funding
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008244 · NIGMS · UNIVERSITY OF MINNESOTA TWIN CITIES · PI SHIMIZU, YOJI · 1988 to 2024
$13.6M
Impact of Cryptococcus Titan Cells on Pathogenesis.R01AI134636 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Kirsten Nielsen · 2018 to 2026
$4.6M
Genomic Research Capacity Building for Cryptococcosis Translational StudiesR01NS118538 · NINDS · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Joel Bazira, David Bisagaya Meya · 2020 to 2026
$3.4M
Continuum of Immune Responses to Cryptococcus neoformansR01AI176922 · NIAID · VIRGINIA POLYTECHNIC INST AND ST UNIV · PI Kirsten Nielsen · 2023 to 2026
$3.0M
Medical Student Summer Research Program in Infection and ImmunityT35AI118620 · NIAID · UNIVERSITY OF MINNESOTA · PI MUELLER, DANIEL L · 2015 to 2025
$351k
The adaptive host response to latent cryptococcosisF30AI155292 · NIAID · UNIVERSITY OF MINNESOTA · PI DING, MINNA · 2021 to 2025
$150k
Assessing the role of SP140 in enhanced resistance to Cryptococcus neoformansF31AI181528 · NIAID · UNIVERSITY OF MINNESOTA · PI Jovany Jordan Betancourt · 2024 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Pulmonary granuloma formation during latent · full record | Socratic